Figline Valdarno, Italy

Nicholas Harmat


Average Co-Inventor Count = 11.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Nicholas Harmat

Introduction

Nicholas Harmat, an accomplished inventor based in Figline Valdarno, Italy, has made significant strides in the field of pharmaceuticals. With a keen focus on developing advanced compounds, he has contributed to medical science through his innovative ideas and research.

Latest Patents

Harmat holds a notable patent for "Linear basic compounds having NK-2 antagonist activity and formulations thereof." This patent describes compounds of formula (I) that are effective as antagonists of tachykinins, particularly neurokinin A. This work highlights his commitment to addressing medical challenges through pharmacological advancements.

Career Highlights

Nicholas Harmat currently works with Menarini Ricerche S.p.a., a well-respected company in the pharmaceutical sector. His role in this organization has allowed him to explore and develop valuable innovations that have potential applications in medicine.

Collaborations

Throughout his career, Harmat has collaborated with esteemed colleagues such as Alessandro Sisto and Valerio Caciagli. These partnerships have fostered an environment of creativity and knowledge sharing, which contributes to the success of their research endeavors.

Conclusion

Nicholas Harmat exemplifies the spirit of innovation in the pharmaceutical industry. His patent on NK-2 antagonist compounds demonstrates not only his expertise as an inventor but also his dedication to improving health outcomes through scientific research. As he continues his work at Menarini Ricerche S.p.a. alongside talented colleagues, the impact of his innovations is sure to be profound in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…